Literature DB >> 18456846

Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Hal P Bogerd1, Bryan R Cullen.   

Abstract

Binding of APOBEC3G to the nucleocapsid (NC) domain of the human immunodeficiency virus (HIV) Gag polyprotein may represent a critical early step in the selective packaging of this antiretroviral factor into HIV virions. Previously, we and others have reported that this interaction is mediated by RNA. Here, we demonstrate that RNA binding by APOBEC3G is key for initiation of APOBEC3G:NC complex formation in vitro. By adding back nucleic acids to purified, RNase-treated APOBEC3G and NC protein preparations in vitro, we demonstrate that complex formation is rescued by short (> or =10 nucleotides) single-stranded RNAs (ssRNAs) containing G residues. In contrast, complex formation is not induced by add-back of short ssRNAs lacking G, by dsRNAs, by ssDNAs, by dsDNAs or by DNA:RNA hybrid molecules. While some highly structured RNA molecules, i.e., tRNAs and rRNAs, failed to rescue APOBEC3G:NC complex formation, other structured RNAs, i.e., human Y RNAs and 7SL RNA, did promote NC binding by APOBEC3G. Together, these results indicate that ternary complex formation requires ssRNA, but suggest this can be presented in the context of an otherwise highly structured RNA molecule. Given previous data arguing that APOBEC3G binds, and edits, ssDNA effectively in vitro, these data may also suggest that APOBEC3G can exist in two different conformational states, with different activities, depending on whether it is bound to ssRNA or ssDNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456846      PMCID: PMC2390788          DOI: 10.1261/rna.964708

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  49 in total

Review 1.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.

Authors:  Yasumasa Iwatani; Hiroaki Takeuchi; Klaus Strebel; Judith G Levin
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.

Authors:  April J Schumacher; Dwight V Nissley; Reuben S Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-06       Impact factor: 11.205

4.  The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules.

Authors:  Susan L Kozak; Mariana Marin; Kristine M Rose; Cory Bystrom; David Kabat
Journal:  J Biol Chem       Date:  2006-08-03       Impact factor: 5.157

5.  Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.

Authors:  Brian P Doehle; Alexandra Schäfer; Heather L Wiegand; Hal P Bogerd; Bryan R Cullen
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.

Authors:  Ya-Lin Chiu; H Ewa Witkowska; Steven C Hall; Mario Santiago; Vanessa B Soros; Cécile Esnault; Thierry Heidmann; Warner C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-09       Impact factor: 11.205

7.  The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.

Authors:  Martin Löchelt; Fabian Romen; Patrizia Bastone; Heide Muckenfuss; Nadine Kirchner; Yong-Boum Kim; Uwe Truyen; Uwe Rösler; Marion Battenberg; Ali Saib; Egbert Flory; Klaus Cichutek; Carsten Münk
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

8.  APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.

Authors:  Hui Chen; Caroline E Lilley; Qin Yu; Darwin V Lee; Jody Chou; Iñigo Narvaiza; Nathaniel R Landau; Matthew D Weitzman
Journal:  Curr Biol       Date:  2006-03-07       Impact factor: 10.834

9.  APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.

Authors:  Hal P Bogerd; Heather L Wiegand; Brian P Doehle; Kira K Lueders; Bryan R Cullen
Journal:  Nucleic Acids Res       Date:  2006-01-10       Impact factor: 16.971

10.  Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.

Authors:  Michael J Wichroski; G Brett Robb; Tariq M Rana
Journal:  PLoS Pathog       Date:  2006-05-12       Impact factor: 6.823

View more
  50 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

Review 3.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

4.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

5.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

6.  Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain.

Authors:  Yuqing Feng; Linda Chelico
Journal:  J Biol Chem       Date:  2011-02-07       Impact factor: 5.157

7.  Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G.

Authors:  Linda Chelico; Courtney Prochnow; Dorothy A Erie; Xiaojiang S Chen; Myron F Goodman
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

8.  Crystal structure of DNA cytidine deaminase ABOBEC3G catalytic deamination domain suggests a binding mode of full-length enzyme to single-stranded DNA.

Authors:  Xiuxiu Lu; Tianlong Zhang; Zeng Xu; Shanshan Liu; Bin Zhao; Wenxian Lan; Chunxi Wang; Jianping Ding; Chunyang Cao
Journal:  J Biol Chem       Date:  2014-12-25       Impact factor: 5.157

9.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

10.  Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition.

Authors:  Yannick Bulliard; Priscilla Turelli; Ute F Röhrig; Vincent Zoete; Bastien Mangeat; Olivier Michielin; Didier Trono
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.